Chimeric antigen receptor T cell based therapeutic modality in solid tumors
10.3969/j.issn.1000-8179.2017.09.201
- VernacularTitle:CAR-T细胞治疗实体瘤的挑战与思考
- Author:
Yang LIU
;
Hongli ZHU
;
Weidong HAN
- Keywords:
chimeric antigen receptor T cell;
solid tumors;
therapeutic modality
- From:
Chinese Journal of Clinical Oncology
2017;44(9):415-417
- CountryChina
- Language:Chinese
-
Abstract:
The CD19-targeted chimeric antigen receptor (CAR) T-cell treatment has achieved clinical success in treating B-cell lineage hematopoietic malignancies. This accomplishment involved the precise and efficient elimination of tumor cells by tumor-associated an-tigen-redirected immune cells. As a result, the reinitiation of several CAR T-cell (CART) based clinical trials in solid tumors was promot-ed. However, developing a feasible and efficient CAR T based therapeutic modality for solid tumors is urgently needed given the differ-ential properties between liquid and solid tumors. In this review, we discuss the advances in the management of cytotherapeutic mo-dality for solid tumors. The aspects considered include toxicity management, target selection, and primer or conditioning treatment.
